Innovent Biologics (HKSE:01801) Gross-Profit-to-Asset % : 29.83% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Innovent Biologics Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Innovent Biologics's annualized Gross Profit for the quarter that ended in Dec. 2023 was HK$6,285 Mil. Innovent Biologics's average Total Assets over the quarter that ended in Dec. 2023 was HK$21,069 Mil. Therefore, Innovent Biologics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 29.83%.

Innovent Biologics Gross-Profit-to-Asset % Historical Data

The historical data trend for Innovent Biologics's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovent Biologics Gross-Profit-to-Asset % Chart

Innovent Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

13.70

37.12

27.18

20.48

26.28

Innovent Biologics Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial										25.12	21.35	21.50	24.51	29.83

Competitive Comparison of Innovent Biologics's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Innovent Biologics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovent Biologics's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovent Biologics's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Innovent Biologics's Gross-Profit-to-Asset % falls into.

Innovent Biologics Gross-Profit-to-Asset % Calculation

Innovent Biologics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	5545.245	/	( (19641.722	+	22561.771)	/ 2 )
	=	5545.245	/	21101.7465
	=	26.28 %

Innovent Biologics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	6284.606	/	( (19575.43	+	22561.771)	/ 2 )
	=	6284.606	/	21068.6005
	=	29.83 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Innovent Biologics Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Innovent Biologics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovent Biologics (HKSE:01801) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovent Biologics Inc (HKSE:01801) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

IVBXF:USA IVBIY:USA 6IB:Germany

Address

168 Dongping Street, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123

Website

https://www.innoventbio.com

Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.

Executives

Jpmorgan Chase & Co.	2502 Approved lending agent
Yu De-chao Michael	2101 Beneficial owner
Temasek Holdings (private) Limited
Brown Brothers Harriman & Co.	2502 Approved lending agent
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you
Morgan Stanley	2201 Interest of corporation controlled by you
Citigroup Inc.	2201 Interest of corporation controlled by you
Shi Yi	2201 Interest of corporation controlled by you
Lav Asset Management (hong Kong) Limited	2102 Investment manager
Eight Roads Investments	2101 Beneficial owner
Fullerton Management Pte Ltd	2201 Interest of corporation controlled by you
Temasek Life Sciences Private Limited	2201 Interest of corporation controlled by you
Tls Beta Pte. Ltd.	2101 Beneficial owner

Innovent Biologics (HKSE:01801) Headlines

No Headlines